Project Grant R44CA298351
Award Date 9/11/25
Completion Date 8/31/27
Dollars Obligated $999K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $399,358 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cordance Medical Inc. aims to optimize a non-invasive focused ultrasound system, called the "NeuroAccess System," to enable liquid biopsies for brain tumor patients. The key objectives are to demonstrate the safety of repeatedly opening the blood-brain barrier, optimize the opening volume and technique in a rat glioma model, and confirm the system's ability to...
- Cordance Medical Inc. received a $998,501 cooperative agreement award from the National Science Foundation under the Engineering program (CFDA 47.041) for the period of July 15, 2021 through June 30, 2023. The award will support Cordance Medical's efforts to develop transcranial dynamic focused ultrasound for the non-invasive opening of the blood-brain barrier, allowing targeted delivery of therapeutic agents to the brain. The Engineering program seeks to improve quality of life and economic...
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $1,165,627 Project Grant under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286) to the Regents of the University of Michigan. The goal of this 4-year grant, awarded on January 15, 2025, is to develop a Transcranial Magnetic Resonance (MR) and Ultrasound (US) Guided Histotripsy (TCMR-USGHT) system for the non-invasive treatment of brain...
- This $1,296,385 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to accelerate the translation and commercialization of a novel, non-invasive wearable rotating magnetic field therapy device (ONCOMAGNETIC DEVICE or OMTX) targeting the treatment of brain cancers. The device generates spinning oscillating magnetic fields that have demonstrated strong, selective anti-cancer effects on patient-derived glioblastoma (GBM) cells and...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- The U.S. National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $349,908 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to Evanesc Therapeutics, Inc. to develop a non-invasive medical device designated "EvaPERMEA" that uses low-power radio frequency evanescent waves to temporarily permeabilize the blood-brain barrier. This innovation aims to improve the delivery of therapeutic...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394), awarded a $244,839 project grant to the University of Virginia. The grant aims to investigate the potential of using magnetic resonance imaging-guided focused ultrasound (MRGFUS) to enhance the delivery and persistence of chimeric antigen receptor (CAR) T cell therapy for pediatric medulloblastoma, a common and challenging brain cancer in children. Under a sub-award,...
- The National Cancer Institute awarded a $679,176 Project Grant to the University of Texas at Dallas (UTD) to develop a novel and minimally invasive method to enhance the delivery of cancer therapies to spinal cord gliomas, test it in a preclinical spinal cord glioma model, and evaluate its application in large animal models. This award is funded through the Cancer Detection and Diagnosis Research program (CFDA 93.394), which supports innovative scientific research to advance cancer screening,...
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $306,463 Project Grant under the CFDA 93.286 "Discovery and Applied Research for Technological Innovations to Improve Human Health" program to Dogpatch Medical LLC, effective September 1, 2025 through August 31, 2026. The grant funding supports the development of PASSIVECATH, an innovative microcatheter device designed for enhanced visibility and targeted drug delivery to the central nervous system...
- The National Cancer Institute (NCI) awarded a $522,491 Cooperative Agreement to Virginia Polytechnic Institute & State University (Virginia Tech) under the Cancer Biology Research (CFDA 93.396) program. The funding supports a 5-year research project to understand the role of interstitial fluid flow in glioblastoma, a deadly brain cancer, and leverage this knowledge to develop novel targeted treatment approaches. The key activities include: Leveraging mathematical modeling to map interstitial...